SCHEMBL2278778

SCHEMBL2278778

COC(=O)CNC(=O)c1cccc(/C=C/C(=O)c2c(OC)cc(C)n(C)c2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.42
P4HB P07237 3/20 0.42
ABCG2 Q9UNQ0 1/20 0.41
ABCB1 P08183 8/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
TXNRD1 Q16881 1/20 0.39
TXNRD3 Q86VQ6 1/20 0.39
TXNRD2 Q9NNW7 1/20 0.39
MEN1 O00255 1/20 0.39
KCNA3 P22001 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278780 1.00 MAPK1 (0.42) MAPK1P4HBABCG2ABCB1SMN1; SMN2
SCHEMBL2280425 0.93 SMN1; SMN2 (0.42) P4HBABCG2ABCB1SMN1; SMN2MAPT
SCHEMBL2280423 0.93 SMN1; SMN2 (0.42) P4HBABCG2ABCB1SMN1; SMN2MAPT
SCHEMBL2281265 0.90 P4HB (0.41) MAPK1P4HBABCG2ABCB1SMN1; SMN2
SCHEMBL2281269 0.90 P4HB (0.41) MAPK1P4HBABCG2ABCB1SMN1; SMN2
SCHEMBL2279763 0.90 ABCG2 (0.45) ABCG2ABCB1SMN1; SMN2MAPTNPSR1
SCHEMBL2279768 0.90 ABCG2 (0.45) ABCG2ABCB1SMN1; SMN2MAPTNPSR1
SCHEMBL2277068 0.89 KDM4E (0.43) P4HBABCG2ABCB1MAPTNPSR1
SCHEMBL2277074 0.89 KDM4E (0.43) P4HBABCG2ABCB1MAPTNPSR1
SCHEMBL2278482 0.89 KDM4E (0.43) P4HBABCG2ABCB1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 MAPK1 3772/4885P4HB 702/4885ABCG2 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.